Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03829540 · ClinicalTrials.gov registry record · Phase 1
CD4CAR for CD4+ Leukemia and Lymphoma
A Phase 1 study of T-Cell Lymphoma and T-cell Leukemia, sponsored by Huda Salman.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 6
- Study locations
NCT03829540 is a Phase 1 study of T-Cell Lymphoma and T-cell Leukemia that is actively recruiting participants, run by Huda Salman. The registered enrollment target is 20 participants, below the 133-participant average among 15 other T-Cell Lymphoma trials with a reported enrollment target (85% lower). The trial reports 6 study locations across 4 states.
The verdict
NCT03829540, a Phase 1 study of T-Cell Lymphoma and T-cell Leukemia, is actively recruiting participants, sponsored by Huda Salman.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 6
- Study locations
Study Summary
This study is designed as a single arm open label Phase I, 3x3, multicenter study of CD4-directed chimeric antigen receptor engineered T-cells (CD4CAR) in patients with relapsed or refractory T-cell leukemia and lymphoma. Specifically, the study will evaluate the safety and feasibility of CD4CAR T-cells. Funding Source - FDA OOPD
Conditions Studied
Interventions
- BIOLOGICAL CD4CAR
Study Locations (6)
Indiana
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center - Indianapolis
- Riley Hospital for Children - Indianapolis
New York
- Albert Einstein Health Network - New York
- Stony Brook Cancer Center - Stony Brook
Florida
- University of Miami Sylvester Comprehensive Cancer Center - Miami
Texas
- The University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2020-07-09 |
| Est. Completion | 2041-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03829540
The ClinicalTrials.gov registry entry for NCT03829540 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 133-participant average among 15 other T-Cell Lymphoma trials with a reported enrollment target (85% lower). The listed sponsor is Huda Salman, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with T-Cell Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which CD4CAR is the first listed.
NCT03829540 reports 6 study locations spanning 4 distinct geographic areas - top geographies include Indiana, New York, Florida.
Frequently Asked Questions
What is clinical trial NCT03829540 about?
NCT03829540 is a clinical study titled "CD4CAR for CD4+ Leukemia and Lymphoma". This study is designed as a single arm open label Phase I, 3x3, multicenter study of CD4-directed chimeric antigen receptor engineered T-cells (CD4CAR) in patients with relapsed or refractory T-cell leukemia and lymphoma. Specifically, the study will evaluate the safety and feasibility of CD4CAR T-c...
What is the current status of trial NCT03829540?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2020-07-09. Estimated completion is 2041-12.
What conditions does trial NCT03829540 study?
This clinical trial studies the following conditions: T-Cell Lymphoma, T-cell Leukemia.
What interventions are being tested in trial NCT03829540?
The interventions under investigation include: CD4CAR (BIOLOGICAL).
Who is sponsoring clinical trial NCT03829540?
This trial is sponsored by Huda Salman, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03829540 being conducted?
This trial has 6 study locations across Florida, Indiana, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for T-Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
RECRUITING · Phase 1
-
Study of Tazemetostat in Lymphoid Malignancies
RECRUITING · Phase 1
-
Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma
RECRUITING · Phase 1
-
Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies
RECRUITING · Phase 1
-
A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.